english

NHS strikes deal on ‘world’s most expensive drug’

England’s National Health Service will roll out a treatment for a rare genetic disorder affecting young children

The NHS has made an agreement to provide young patients with the most expensive drug in the world, a one-off life-saving treatment which is reportedly priced at £2.8 million ($3.7 million).

“But it can now be offered to young patients on the NHS in England after the health service negotiated a significant confidential discount,” the NHS said in a statement on Friday.

Developed by British firm Orchard Therapeutics, the drug Libmeldy is used to treat metachromatic leukodystrophy (MLD), a rare and fatal genetic disorder in babies and young children.

“The deal we have struck is just the latest example of NHS England using its commercial capabilities,” NHS England Chief Executive Amanda Pritchard said, adding that the service continues to provide “patients with cutting-edge treatments and therapies at a price that is fair to taxpayers.”

Orchard Therapeutics CEO Professor Bobby Gaspar said the deal was “a major milestone for the MLD community” and a testament to “the potential for durable effects” of gene therapy.

Read more

FILE PHOTO: Light micrograph of blood cells (dark purple) in the liver of a patient with lymphocytic leukemia.
Gene therapy ‘cured’ leukemia patients, doctors say

MLD is caused by a genetic mutation that results in the build-up of fats in the cells of the brain, spinal cord, peripheral nerves, and other organs, such as the liver and kidneys. Over time, the nerves and other parts of the body stop working, causing progressive loss of sight, speech, and hearing, as well as the ability to walk.

The disorder first develops in babies younger than 30 months. The average life expectancy of children suffering from MLD is between just five and eight years old. MLD also occurs in teenagers and adults, but less frequently.

Around four babies are born with MLD in England every year, according to the BBC.

source: RT




Împotriva articolelor redacției noastre, persoanele nemulțumite pot formula Contestație în termen de 10 zile de la publicarea articolului, la judecătoria Orășenească nr. 1 München Bayern Deutschland, in conformitate cu Legea federală Germană. Considerăm că nu se pot formula acțiuni la instanțele din România deoarece nici o persoană care activează în trustul nostru nu poate fi extrasă de sub jurisdicția federală germană. Considerăm că redacția noastră nu răspunde în fața autorităților din România ci doar celor federale sau civile germane. deoarece legea română nu are efecte de extraneitate asupra redacției chiar dacă subiectul știrilor face obiectul unor evenimente sau persoane din România și sunt scrise în limba română. Limba română nu este izvor de extraneitate a legii.

(Visited 11 times, 1 visits today)
Avatar
Marius Leontiuc
absolvent WEB DESIGN Academia Britanică de Comunicare Iasi - absolvent COMUNICARE IN AFACERI Academia Britanica de Afaceri si Comunicare -absolvent JURNALISM EDITORIAL - London School University - 2019 inscris la echivalare diploma la Universitatea Politehnica Timisoara - absolvent studii de Drept Universitatea Europeană Drăgan, cursuri in Drept la Universitatea de Vest Timisoara, absolvent studii de proiectare, pastor coordonator in Biserica Protestanta Evanghelica, Android Developer pe Google Play și plugin developer la Oxwall, creator de teme Wordpress și Oxwall, operator Wordpress, Drupal, Oxwall, Osclass, Moodle, tehnologii HTML și PHP
http://www.leontiucmarius.wordpress.com/cv

Lasă un răspuns

Adresa ta de email nu va fi publicată. Câmpurile obligatorii sunt marcate cu *